DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Penile Carcinoma — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePenile Carcinoma maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for penile carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
HRas proto-oncogene, GTPase (HRAS) — HRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8ELT · 1.66 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Penile carcinoma is a rare male cancer; in some countries it accounts for up to 10% of all male malignancies. If diagnosed early, over 80% of cases can be cured, but local treatment can be mutilating and cause long-term sexual dysfunction, voiding problems, and poor cosmetic appearance. Organ-preserving treatment appears to allow better quality of life and sexual function and should be offered when feasible. There is little published data on the psychosocial impact of the disease.
A 2017 study presented the first genetically engineered mouse models of penile squamous cell carcinoma. Mice with deletion of Smad4 and Apc developed primary penile tumours at 18–20 weeks of age; adding deletion of Pten accelerated tumour onset to 8–10 weeks. In vivo treatment with cisplatin in 6 mice per group showed that loss of Pten mediated tumour resistance to cisplatin. Transcriptomic analysis indicated that COX-2 may be the master regulator of the tumours’ inflammatory phenotype, which featured massive infiltration of CD11b+ Gr1+ myeloid cells. Reverse phase protein array analysis identified a number of highly regulated proteins and pathways in Smad4;Apc tumours compared with normal penis.
Based on those protein array results, the researchers were testing sensitivities of isolated penile cancer cell lines to a panel of 50 drugs targeting pathways including PI3K/AKT/mTOR, HER2/EGFR, SRC, JAK, STAT3, and Bcl-XL. They also developed four patient-derived xenograft models and isolated cell lines that grew squamous cell carcinoma in SCID mice from two of the four models. These models are intended to help validate findings from the transgenic mice and to study tumour pathogenesis, progression, and novel therapeutic strategies.
What is still missing is any clinical trial data in humans for the drugs being tested in the mouse and cell-line models. The mouse model itself is new and has not yet been used to identify a therapy that translates to patients. No patient stratification strategy has been proposed, and the funding and infrastructure needed to move from these preclinical tools to a clinical trial in a rare cancer like penile carcinoma remain unspecified.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Scientific World JOURNAL · 2011 · 47 citations · open access
Penile Carcinoma: Risk Factors and Molecular Alterations
AbstractPenile carcinoma is a rare, male cancer. Although the incidence of penile carcinoma is very low in Western countries, in some countries, the incidence is significantly greater, with penile carcinoma accounting for ≤10% of all male malignancies. Greater insight has been gained in recent years as to its pathogenesis, the risk factors associated with its development, and the clinical and histological precursor lesions related to this disease. In this review, risk and conditions factors for penile carcinoma, molecular alterations in this type of cancer, histological types, and prognostic factors will be discussed in order to further our understanding of the biology and behavior of this cancer.
Translational Andrology and Urology · 2017 · 43 citations · open access
Psychosocial impact of penile carcinoma
AbstractPenile carcinoma is a rare malignancy with a potential for local invasion and regional/distant extension. Penile cancer can be cured in over 80% of cases if diagnosed early. However, local treatment, although potentially lifesaving, can be mutilating and devastating for the patient's psychological well-being. In patients with long-term survival after penile cancer, sexual dysfunction, voiding problems and cosmetic penile appearance may adversely affect the patient's quality of life. Although there is little data in the literature about psychosocial impact of penile carcinoma, organ-preserving treatment seems to allow for better quality of life and sexual function and should be offered to all patients whenever feasible.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
